High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus:: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins

被引:37
作者
Chatelain, D [1 ]
Fléjou, JF [1 ]
机构
[1] Hop St Antoine, Serv Anat Pathol, F-75541 Paris 12, France
关键词
Barrett's esophagus; adenocarcinoma; dysplasia; p53; protein; p21;
D O I
10.1007/s00428-002-0674-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In order to characterize the early morphological and molecular stages of the neoplastic progression of Barrett's mucosa, we performed the entire histological examination of ten specimens of resected Barrett's esophagus with high-grade dysplasia or superficial adenocarcinoma. The expression of p53, p21 and Bcl-2 proteins was assessed by immunohistochemistry. The surface of Barrett's mucosa ranged from 2.6 cm(2) to 31 cm(2). Dysplasia and adenocarcinoma always developed in specialized mucosa and often occupied small surfaces. High-grade dysplasia was multifocal in eight cases. There was no preferential site for neoplastic transformation into high-grade dysplasia or superficial adenocarcinoma in Barrett's mucosa. Three superficial adenocarcinomas and four high-grade dysplasias overexpressed p53 protein. p21 protein was focally expressed in nondysplastic mucosa and overexpressed in two superficial adenocarcinomas, one high-grade dysplasia and two low-grade dysplasias. In most cases, the expression of p21 and p53 proteins was unrelated. Bcl-2 protein was detected in only one area of low-grade dysplasia. In our study, high-grade dysplasia and superficial adenocarcinoma appeared as tiny lesions, often multifocal for high-grade dysplasia confirming the need for an extensive sampling of Barrett's mucosa in the endoscopic surveillance. p53 dysfunction plays a major role in the progression from dysplasia to carcinoma in Barrett's esophagus and appears unrelated to p21 and Bcl-2 expression.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 40 条
[1]  
Cameron AJ, 1997, AM J GASTROENTEROL, V92, P586
[2]  
CLARKE MR, 1996, MODERN PATHOL, V9, pA59
[3]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[4]  
ELSEN GM, 1999, GASTROINTEST ENDOSC, V50, P814
[5]   OVEREXPRESSION OF P53 PROTEIN IN BARRETTS SYNDROME WITH MALIGNANT TRANSFORMATION [J].
FLEJOU, JF ;
POTET, F ;
MUZEAU, F ;
LEPELLETIER, F ;
FEKETE, F ;
HENIN, D .
JOURNAL OF CLINICAL PATHOLOGY, 1993, 46 (04) :330-333
[6]  
GOLDBLUM JR, 1995, MODERN PATHOL, V8, P866
[7]   BARRETTS ESOPHAGUS - DEVELOPMENT OF DYSPLASIA AND ADENOCARCINOMA [J].
HAMEETEMAN, W ;
TYTGAT, GNJ ;
HOUTHOFF, HJ ;
VANDENTWEEL, JG .
GASTROENTEROLOGY, 1989, 96 (05) :1249-1256
[8]   TP53 GENE-MUTATIONS AND P53 PROTEIN IMMUNOREACTIVITY IN MALIGNANT AND PREMALIGNANT BARRETTS-ESOPHAGUS [J].
HAMELIN, R ;
FLEJOU, JF ;
MUZEAU, F ;
POTET, F ;
LAURENTPUIG, P ;
FEKETE, F ;
THOMAS, G .
GASTROENTEROLOGY, 1994, 107 (04) :1012-1018
[9]  
Hanas JS, 1999, CANCER-AM CANCER SOC, V86, P756, DOI 10.1002/(SICI)1097-0142(19990901)86:5<756::AID-CNCR9>3.0.CO
[10]  
2-X